Company Overview of OvaScience, Inc.
OvaScience, Inc., a life science company, engages in the discovery, development, and commercialization of new treatments for infertility. The company’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman's own ovaries. It is developing and commercializing various fertility treatment options designed to enhance egg health and revolutionize in vitro fertilization (IVF) comprising AUGMENT to improve the energy and health of the woman’s eggs by using mitochondria from a woman's EggPC cells; OvaPrime treatment for boosting a woman's egg reserve by transferring the EggPCs from woman's own ovaries;...
215 First Street
Cambridge, MA 02142
Founded in 2011
Key Executives for OvaScience, Inc.
Co-Founder, Chief Executive Officer and Director
President and Chief Scientific Officer
Total Annual Compensation: $644.0K
Chief Commercial Officer
Total Annual Compensation: $21.1K
Compensation as of Fiscal Year 2014.
OvaScience, Inc. Key Developments
OvaScience Appoints Revi Mehrotra as the Chief Corporate Development Officer
Jun 23 15
OvaScience has named Revi Mehrotra as the chief corporate development officer. Mehrotra was recently global head of biotechnology equity research at Credit Suisse.
OvaScience, Inc. Appoints John Eisel as Executive Vice President of Global Site Operations, and Gabriel M. Cohn as Head of Medical Affairs and Translational Medicine
Jun 5 15
OvaScienceSM announced two new positions that support OvaScience™s expanding international operations. John Eisel has joined the Company as Executive Vice
President of Global Site Operations, and Gabriel M. Cohn, M.D., has joined as Head of Medical Affairs and Translational Medicine. Mr. Eisel joins from InnerWorkings LLC, where he served as Chief Operating Officer since 2011. Prior to that, he was Divisional Vice President of Strategic Operations, Pharmacy Services for Walgreens. He also held roles of increasing responsibility at McKinsey & Company, including serving as Associate Principal. Mr. Eisel began his career at PricewaterhouseCoopers, serving as a Senior Associate in Financial Advisory Services. Dr. Cohn is a Board-certified OB/GYN and Clinical Geneticist who previously served as the Chief of the Division of Clinical and Reproductive Genetics Department at Baystate Medical Center and the Director of Reproductive Genetics, Division of Maternal Fetal Medicine at SUNY Health Science Center (HSC) at Syracuse. Dr. Cohn joins OvaScience from Shire, where he held roles that included Medical Director and Interim Medical Lead for the Gaucher Disease Franchise and the Senior Medical Director of Clinical Sciences.
OvaScience Appoints John P. Howe to the Board of Directors
Jun 5 15
OvaScience announced the appointment of John P. Howe, III, M.D., former President and Chief Executive Officer of Project HOPE, to the OvaScience Board of Directors.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries